BRCA2 and cancer: In work published earlier this year (Kong et al., 2024), we have been able to show that an aldehyde byproduct of glycolysis, methylglyoxal, can inactivate BRCA2 by protein degradation, triggering genome-wide patterns of single-base substitution mutations that are implicated in cancer initiation.